Compare Quest Diagnostics Inc (DGX) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Endeavour Silver Corp — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Endeavour Silver Corp trades at $8.65 (market cap $2.54B). The key difference: Quest Diagnostics Inc is far larger — about 10× Endeavour Silver Corp's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Endeavour Silver Corp for 25 Days on average.
| DGX | EXK | |
|---|---|---|
Market Cap | $25.48B | $2.54B |
Volume | 941,866 | 7,077,330 |
Sector | Health | Basic Materials |
52-Week High | $247.45 | $14.12 |
52-Week Low | $173.49 | $7.07 |
Typical Hold Time | 56 Days | 25 Days |
Enterprise Value | $31.23B | $2.54B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
Endeavour Silver (EXK) trades at $8.57, up 3.0% today, amid a bearish technical signal from moving averages but with neutral oscillators. The company reported a net loss of $119.1 million in 2025, though 2026 projections show a turnaround to a $66 million net profit. Recent news highlights operational progress at the Terronera and Kolpa mines, alongside temporary disruptions now resolved.
The outlook is mixed: strong analyst buy consensus (78.57%) and projected 2026 profitability support upside, but high P/E of 42.85 and operational risks from mine blockades pose challenges. Investment appeal hinges on execution of growth projects and silver price stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
